BioGenetics Seeks To Boost Pharma Business Via Kyung Nam Acquisition
South Korean medical product manufacturer BioGenetics, which has recently diversified into the biopharma business and entered alliances for novel anticancer drugs, aims to further beef up its pharma activities through the acquisition of Kyung Nam Pharm, which will secure distribution networks at home and abroad.
You may also be interested in...
Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth.
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.